SCHEMBL3880397

SCHEMBL3880397

CN(C)c1ccc(NC(=O)Nc2ccc(-c3c(C(N)=O)[nH]c4ccccc34)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 7/20 0.59
PDGFRB P09619 4/20 0.49
KDR P35968 4/20 0.49
MAPT P10636 4/20 0.49
RAB9A P51151 4/20 0.49
NOX1 Q9Y5S8 4/20 0.49
GAA P10253 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPK1 P28482 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
HPGD P15428 1/20 0.45
NPC1 O15118 2/20 0.43
TP53 P04637 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ESR2 Q92731 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879937 0.91 KDR (0.55) MAP2PDGFRBKDRMAPTRAB9A
SCHEMBL3880122 0.88 KDR (0.58) MAP2PDGFRBKDRMAPTRAB9A
SCHEMBL3879170 0.88 MAP2 (0.72) MAP2PDGFRBKDRGAAKDM4E
SCHEMBL3884472 0.87 MAP2 (0.63) MAP2PDGFRBKDRRAB9AGAA
SCHEMBL3879403 0.85 MAP2 (0.63) MAP2PDGFRBKDRGAAKDM4E
SCHEMBL3883640 0.85 MAP2 (0.63) MAP2PDGFRBKDRMAPTRAB9A
SCHEMBL3883071 0.84 KDR (0.60) MAP2PDGFRBKDRGAAKDM4E
SCHEMBL3888326 0.84 MAP2 (0.59) MAP2PDGFRBKDRMAPTRAB9A
SCHEMBL3877576 0.84 MAP2 (0.59) MAP2PDGFRBKDRMAPTRAB9A
SCHEMBL3888349 0.84 MAP2 (0.59) MAP2PDGFRBKDRMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566736-B2 Substituted indoles, compositions containing them, method for the production thereof and their use AVENTIS PHARMA S.A. (FR) 2009-07-28 US claimed
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use AVENTIS PHARMA S.A. (FR) 2007-11-08 US claimed
EP-1841762-A1 SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE Aventis Pharma S.A. (FR) 2007-10-10 EP claimed
WO-2006061493-A1 SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AVENTIS PHARMA S.A. (FR) 2006-06-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use IDO1, RB1, IDO2 MAP2 1170/4885PDGFRB 1177/4885KDR 1690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.